Supplemental Table 2. 120 high-frequency citations of PCOS related articles retrieved from Web of Science Core Collection during 2000-2017

Rank.	Author	Published Year	Title	Citations
1	Fauser BCJM	2004	Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)	1176
2	Chang J	2004	Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome	1103
3	Dunaif AC	1997	Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.	1015
4	Matthews DR	1985	Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.	960
5	Azziz R	2004	The prevalence and features of the polycystic ovary syndrome in an unselected population.	848
6	Franks S	1995	Polycystic ovary syndrome	774
7	Ferriman D	1961	Clinical assessment of body hair growth in women.	739
8	Knochenhauer ES	1998	Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study.	729
9	Legro RS	1999	Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women.	703
10	Dunaif A	1989	Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome.	679
11	Ehrmann DA	2005	Polycystic ovary syndrome.	616
12	Asuncion M	2000	A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain.	577
13	Zawadski JK	1992	Diagnostic criteria for polycystic ovary syndrome,towards a rational approach	577
14	Ehrmann DA	1999	Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.	486
15	Azziz R	2006	Positions statement: criteria for defining polycystic ovary syndrome as a	449

			predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline.	
16	Diamanti-Kandarakis E	1999	A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile.	448
17	Rotterdam ESHRE	2004	Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.	400
18	Azziz R	2009	The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report.	399
19	Norman RJ	2007	Polycystic ovary syndrome.	365
20	Hatch R	1981	Hirsutism: implications, etiology, and management.	339
21	Vermeulen A	1999	A critical evaluation of simple methods for the estimation of free testosterone in serum.	339
22	March WA	2010	The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria.	332
23	Balen AH	2003	Ultrasound assessment of the polycystic ovary: international consensus definitions.	321
24	Nestler JE	1998	Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome.	297
25	Adams J	1986	Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism.	296
26	Legro RS	1998	A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome.	288
27	Velazquez EM	1994	Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.	280
28	Apridonidz-e T	2005	Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome.	274
29	Stein IF	1935	Amenorrhea associated with bilateral polycystic ovaries	273
30	Matsuda M	1999	Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin	271

			clamp.	
31	Moghetti P	2000	Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.	266
32	Goodarzi MO	2011	Polycystic ovary syndrome: etiology, pathogenesis and diagnosis.	264
33	Wild RA	2010	Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society.	257
34	Legro RS	1998	Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome.	244
35	Fauser BCJM	2012	Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group.	239
36	Nestler JE	1996	Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome.	237
37	Katz A	2000	Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans.	235
38	Wild S	2000	Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study.	232
39	Gambineri A	2002	Obesity and the polycystic ovary syndrome.	229
40	Kelly CCJ	2001	Low grade chronic inflammation in women with polycystic ovarian syndrome.	225
41	Legro RS	2007	Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.	223
42	Diamanti-Kandarakis E	2012	Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.	212
43	Ehrmann DA	2006	Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome.	211
44	Polson DW	1988	Polycystic ovaries--a common finding in normal women.	211
45	Friedewald	1972	Estimation of the concentration of	210

	WT		low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.	
46	Moran LJ	2010	Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis.	210
47	Kiddy DS	1992	Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome.	207
48	Nestler JE	1991	A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome.	204
49	Burghen GA	1980	Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease.	203
50	Urbanek M	1999	Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin.	202
51	Talbott EO	2000	Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women.	202
52	Azziz R	2001	Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial.	201
53	Adams J	1985	Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone.	198
54	Nestler JE	1998	Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositol glycan mediators as the signal transduction system.	195
55	Pigny P	2003	Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest.	193
56	Lord JM	2003	Metformin in polycystic ovary syndrome: systematic review and meta-analysis.	191
57	Legro RS	2003	Polycystic ovary syndrome and cardiovascular disease: a premature association?	190

58	Knowler WC	2002	Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.	189
59	Azziz R	2004	Androgen excess in women: experience with over 1000 consecutive patients.	188
60	Dahlgren E	1992	Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women.	188
61	Legro RS	2001	Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome.	187
62	Balen AH	1995	Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients.	186
63	Paradisi G	2001	Polycystic ovary syndrome is associated with endothelial dysfunction.	186
64	Pasquali R	2000	Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.	185
65	Talbott E	1995	Coronary heart disease risk factors in women with polycystic ovary syndrome.	184
66	Dahlgren E	1992	Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones.	180
67	Legro RS	2013	Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline.	180
68	Ehrmann DA	1995	Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion.	176
69	Dunaif A	1987	Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia.	175
70	Carmina E	1999	Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women.	174
71	Boomsma CM	2006	A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome.	171
72	Chang RJ	1983	Insulin resistance in nonobese patients	171

			with polycystic ovarian disease.	
73	Shaw LJ	2008	Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation.	169
74	Deugarte CM	2005	Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment.	165
75	Poretsky L	1999	The insulin-related ovarian regulatory system in health and disease.	165
76	Taylor AE	1997	Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome.	164
77	Pierpoint T	1998	Mortality of women with polycystic ovary syndrome at long-term follow-up.	163
78	Dunaif A	1996	The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.	162
79	Nelson VL	1999	Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries.	157
80	Nestler JE	1997	Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens.	157
81	Wild RA	1985	Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome.	156
82	Laven JSE	2004	Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age.	155
83	Conway GS	1992	Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome.	154
84	Orio F	2004	Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome.	154
85	Legro RS	2004	Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls.	153
86	Rotterdam	2004	Revised 2003 consensus on diagnostic	153

	ESHRE		criteria and long-term health risks related to polycystic ovary syndrome (PCOS).	
87	Dunaif A	1992	Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome.	152
88	Dunaif A	1996	Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome.	151
89	Huber-Buchholz MM	1999	Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone.	147
90	Carmina E	1992	Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome?	146
91	Morales AJ	1996	Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features.	146
92	Ovalle F	2002	Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus.	146
93	Weenen C	2004	Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment.	145
94	Dunaif A	1995	Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome.	143
95	Chen ZJ	2011	Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3.	143
96	Coviello AD	2006	Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance.	142
97	Abbott DH	2005	Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome?	138
98	Christian RC	2003	Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome.	138
99	Teede H	2010	Polycystic ovary syndrome: a complex	137

			condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan.	
100	Barbieri RL	1986	Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism.	136
101	Manneras L	2007	A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome.	135
102	Ehrmann DA	1997	Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome.	134
103	Nestler JE	1999	Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.	134
104	Ehrmann DA	1995	Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus.	133
105	Jakubowicz DJ	2002	Effects of metformin on early pregnancy loss in the polycystic ovary syndrome.	131
106	Pigny P	2006	Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome.	131
107	Tarkun I	2004	Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation.	129
108	Talbott E	1998	Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study.	128
109	Birdsall MA	1997	Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization.	127
110	Palmert MR	2002	Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome.	127
111	Abbott DH	2002	Developmental origin of polycystic ovary syndrome - a hypothesis.	126
112	Dunaif A	2001	Current concepts in the polycystic ovary syndrome.	125

113	Gillingsmit-h C	1994	Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries.	125
114	Glueck CJ	2003	Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome.	125
115	Franks S	1989	Polycystic ovary syndrome: a changing perspective.	123
116	Orio F	2004	The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study.	122
117	Barber TM	2006	Obesity and polycystic ovary syndrome.	121
118	Holte J	1995	Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome.	121
119	Glueck CJ	2001	Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study.	121
120	Lo JC	2006	Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome.	121